2014 CME Symposia - Lunch Symposium B
Register for the CMHC today to sign up for these value-added CME/CE activities-at no additional cost!
Pre-registration for symposia will open at the end of August for CMHC registrants to make selections. There are no additional fees to attend. Symposia include meals or refreshments and seating is limited and on a first-come, first-serve basis.
CME Lunch Symposium B
Thursday · 12:45 - 2:15pm
Closing the Gaps in the Continuum of Care for Patients with Acute Coronary Syndromes:
Implications for Optimal Antiplatelet Use
Supported by an educational grant from AstraZeneca
The manifestations of Acute Coronary Syndrome (ACS) are associated with high morbidity and mortality. This symposium will provide an update on major U.S. guideline recommendations concerning the use of P2Y12 inhibitors in patients with ACS. Our faculty of internationally recognized experts will present and analyze clinical trial data on the available P2Y12 inhibitors, with an emphasis on clinical data in high-risk patients such as the elderly, those with diabetes, and those with a prior history of stroke. Attendees will leave this activity better able to individualize antiplatelet therapy, improve outcomes and minimize hospital readmission rates.
- Identify ACS patients with high-risk comorbidities who would benefit from more intensive platelet inhibition therapy, and adjust treatment strategies accordingly.
- Select an appropriate antiplatelet treatment regimen based upon clinical trial data and an understanding of the different clinical attributes and risk of adverse events of existing agents.
- Implement strategies to incorporate clinical practice guidelines, protocols, and quality improvement measures to refine discharge planning and follow-through to ensure continuance of quality health care delivery to patients after hospital discharge.
Preliminary Agenda & Faculty
|12:45 - 1:05pm
||Treatment Strategies for ACS patients: P2Y12 Antiplatelet Agent Across the ACS Spectrum
||Chairperson: Deepak L. Bhatt, MD, MPH
|1:05 - 1:20pm
||Upstream Therapy: Does Timing of Antiplatelet Therapy Matter?
||Presenter: P. Gabriel Steg, MD
|1:20 - 1:35pm
||High Risk Patients with ACS: What Are the Concerns
||Presenter: Robert A. Harrington, MD
|1:35 - 1:50pm
||Minimizing Readmission Rates Post-ACS: Why Should Clinicians Care?
||Presenter: Jeffrey L. Anderson, MD
|1:50 - 2:15pm
||Moderator: Deepak L. Bhatt, MD, MPH
Discussants: Jeffrey L. Anderson, MD; Robert A. Harrington, MD; P. Gabriel Steg, MD
Deepak L. Bhatt, MD, MPH
- Professor of Medicine
- Harvard Medical School
- Executive Director
- Interventional Cardiovascular Programs
- Brigham and Women's Hospital Heart and Vascular Center
- Boston, MA
Jeffrey L. Anderson, MD
- Professor of Medicine
- University of Utah School of Medicine
- Associate Chief of Cardiology
- Director, Cardiovascular Research
- Intermountain Heart Institute
- Intermountain Medical Center
Robert A. Harrington, MD
Arthur L. Bloomfield Professor of Medicine
Chairman of the Department of Medicine
P. Gabriel Steg, MD
- Professor, Cardiology Department
- Paris Diderot University
- Director, Coronary Care Unit
- Hospital Bichat-Claude Bernard
- Paris, France
View Complete Accreditation Details and Program Overview: CMHC Accreditation